What would be your second line approach for a patient with MSI-H metastatic colon cancer who progressed on first line chemotherapy?

I would definitely favor nivolumab + ipilimumab in this setting. Although we don't have a randomized comparison, the response rate, duration of response, and PFS reported in CheckMate 142 clearly exceed what we would expect with second-line chemotherapy. This is even more remarkable when you conside...